Henry Schein, Inc. $HSIC Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 3.1% in the fourth quarter, HoldingsChannel reports. The firm owned 2,733,878 shares of the company’s stock after selling 87,567 shares during the quarter. Geode Capital Management LLC’s holdings in Henry Schein were worth $206,277,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HSIC. AQR Capital Management LLC boosted its position in Henry Schein by 47.3% during the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock worth $2,071,000 after acquiring an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after acquiring an additional 229 shares during the period. Acadian Asset Management LLC acquired a new position in Henry Schein during the 1st quarter worth $676,000. Cetera Investment Advisers boosted its position in Henry Schein by 12.9% during the 2nd quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock worth $406,000 after acquiring an additional 637 shares during the period. Finally, First Trust Advisors LP boosted its position in Henry Schein by 0.8% during the 2nd quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock worth $16,154,000 after acquiring an additional 1,669 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insider Buying and Selling at Henry Schein

In related news, CEO Thomas C. Popeck sold 1,355 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the sale, the chief executive officer directly owned 86,182 shares in the company, valued at $6,273,187.78. The trade was a 1.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Philip A. Laskawy sold 2,844 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $80.36, for a total value of $228,543.84. Following the sale, the director directly owned 21,961 shares of the company’s stock, valued at approximately $1,764,785.96. This represents a 11.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 7,043 shares of company stock valued at $551,737 over the last quarter. Company insiders own 0.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HSIC. Mizuho reduced their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Wells Fargo & Company boosted their price target on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. UBS Group reiterated a “neutral” rating and set a $85.00 price target (down from $87.00) on shares of Henry Schein in a research report on Wednesday, May 6th. Morgan Stanley reiterated an “underweight” rating and set a $64.00 price target (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Finally, JPMorgan Chase & Co. lifted their price target on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $86.83.

Henry Schein Stock Down 0.5%

NASDAQ HSIC opened at $76.04 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75. The company’s 50 day simple moving average is $74.49 and its 200 day simple moving average is $75.85. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $89.29. The company has a market capitalization of $8.66 billion, a P/E ratio of 22.97, a PEG ratio of 1.91 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same period in the previous year, the firm earned $1.15 EPS. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities research analysts expect that Henry Schein, Inc. will post 5.32 earnings per share for the current fiscal year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.